Antihyperglycemic treatment in diabetics with coronary disease: Increased metformin-associated mortality over a 5-year follow-up

Cardiology

Volumn 91, Issue 3, 1999, Pages 195-202

  Fisman, Enrique Z ^a,b   Tenenbaum, Alexander ^a   Benderly, Michal ^a   Goldbourt, Uri ^a   Behar, Solomon ^a   Motro, Michael ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Coronary disease; Diabetes mellitus; Metformin; Mortality; Sulfonylureas

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN; SULFONYLUREA;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET THERAPY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; SURVIVAL ANALYSIS;

EID: 0032877022     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000006909     Document Type: Article

References (37)

1. Bornstein NM: Epidemiology of stroke; in Daniel WG, Kronzon I, Mugge A (eds): Cardiogenic Embolism. Baltimore, Williams & Wilkins, 1996, pp 1-6.
2. Kessler I: Mortality experience in diabetic patients. Am J Med 1971;51:715-724.
3. Pyorala K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: An epidemiological view. Diabetes Metab Rev 1987;3:463-524.
4. Robertson W, Strong J: Atherosclerosis in persons with hypertension and diabetes mellitus. Lab Invest 1968;18:538-551.
5. Hamby R, Sherman L, Mehta J, Aintablian A: Reappraisal of the role of the diabetic state in coronary artery disease. Chest 1976;70:251-257.
6. Turner RC, Holman RR: The UK prospective diabetes study. Ann Med 1996;28:439-444.
7. Klimt CR, Knatterud GL, Meinert CL, Prout TE: The University Group Diabetes Program; a study of the effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods and baseline characteristics. II. Mortality results. Diabetes 1970;19(suppl 2):747-830.
8. Innerfield RJ: Metformin-associated mortality in US studies. N Engl J Med 1996;334:1611-1613.
9. American Diabetes Association Consensus Statement: The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1996;19:S54-S61.
10. Goldbourt U, Behar S, Reicher-Reiss H, et al: Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993;71:909-915.
11. Benderly M, Graff E, Reicher-Reiss H, Behar S. Brunner D, Goldbourt U: Fibrinogen is a predictor of mortality in coronary artery disease patients. Arterioscler Thromb Vase Biol 1996;16:351-356.
12. International Classification of Diseases: Clinical Modification, 9th revision. Ann Arbor, Edwards, 1981, vol 1.
13. SAS Institute: SAS/STAT. User's Guide, version 6, ed 4. Cary, SAS Institute, 1987, vol 2.
14. Yaari S, Goldbourt U: A SAS program for evaluating person-years of risk in cohort studies. Comput Biol Med 1989;19:353-359.
15. SAS/STAT software: Changes and Enhancements, release 6.07. SAS technical report P-229. Cary, SAS Institute, 1992, p 620.
16. Goldner MG, Knatterud GL, Prout TE: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. III. Clinical implication of UGDP results. JAMA 1971;218:1400-1410.
17. DeFronzo RA, Barzilai R, Simonson DC: Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991;73:1294-1301.
18. Grant PJ: The effects of high and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996;19:64-66.
19. Carlsen SM, Rossvoll O, Bjervc KS, Foiling I: Metformin improves lipid pattern in nondiabetic patients with coronary heart disease. J Intern Med 1996;239:227-233.
20. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus, N Engl J Med 1995;333:541-549.
21. 12 and intrinsic factor secretion during biguanide therapy. Diabetologia 1983;24:16-18.
22. Mayer EL, Jacobsen DW, Robinson K: Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-527.
23. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337: 230-236.
24. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM: Homocysteine and ischemic heart disease. Results of a prospective study with implications regarding prevention. Arch Intern Med 1998;158:862-867.
25. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA: Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265-266.
26. Marchetti P, Navalesi R: Pharmacokinetic-pharmacodynamic relationships of oral hypoglyccmic agents: An update. Clin Pharmacokinet 1989;16:100-128.
27. Smits P, Thien T: Cardiovascular effects of sulphonylurea derivatives. Implication for the treatment of NIDDM? Diabetologia 1995;38: 116-121.
28. Brady PA, Terzic A: The sulfonylurea controversy: More questions from the heart. J Am Coll Cardiol 1998;31:950-956.
29. + ATP channels in coronary vasodilation during exercise. Circulation 1993;88:1245-1253.
30. + channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991;69:571-581.
31. Grover GJ, Sleph PG, Dzwonick BS: Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interactions with adenosine A1-receptors. Circulation 1992;86:1310-1316.
32. Klimt CR, Canner PL, Jacobs DR, Tominaga S: The prognostic importance of plasma glucose levels and of the use of oral hypoglycemic drugs after myocardial infarction in men. Diabetes 1977;26:453-465.
33. Herman LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A: Therapeutic comparison of metformin and sulphonylurea, alone and in various combinations. Diabetes Care 1994;17:1100-1109.
34. UK Prospective Diabetes Study Group. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998;21:87-92.
35. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998:352: 837-853.
36. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in over-weight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
37. Nathan DM: Some answers, more controversy, from UKPDS. Lancet 1998;352:832-833.